SBIR/STTR Research Award
Development of Novel Brown Adipocyte Recruiters for the Treatment of Obesity
Award amount
$295,420Program and phase
SBIR · Phase IAward year
2020Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ENERGESIS PHARMACEUTICALS INC
- Proposal award date
- 2020-07-01
- Contract end date
- 2021-06-30
- UEI
- JA9AEU5KN7R1
- Solicitation number
- PA19-272
- Topic code
- NIDDK
Research abstract
PROJECT SUMMARY/ABSTRACT
Obesity has reached epidemic proportions in the U.S. and plays a major role in the development of type 2
diabetes, dyslipidemia, and cardiovascular disease. There remains a very significant need for better non-
surgical treatments. While most current weight loss agents act by suppressing appetite, strategies that can
safely enhance energy expenditure have the potential to effectively treat obesity. Brown adipose tissue (BAT)
is a thermogenic tissue that uniquely expresses mitochondrial UnCoupling Protein-1 (UCP1). This protein
dissipates, in a regulated fashion, the electrochemical gradient in the mitochondria of brown adipocytes as
heat, and thus plays an important role in the maintenance of body temperature and energy balance in
rodents and humans. BAT is a flexible tissue that normally enlarges or atrophies over time depending on
environmental temperature. In many different rodent models, enhancement of BAT mass has convincingly
been shown to lead to weight loss and diabetes resistance. While BAT was until recently thought to be
effectively nonexistent in adult humans, data obtained in the past several years show that adults in fact have
significant BAT and that this tissue is functional. It has been well established that a higher amount of active
BAT in individuals is strongly correlated with leanness. Cold exposure in humans leads to increased BAT
formation, thermogenesis, insulin sensitivity, and lipolysis, demonstrating that BAT can be recruited and lead
to metabolic benefits. Moreover, the genetic locus most tightly linked with general obesity causes defective
recruitment of new brown adipocytes.
Until recently no brown adipocyte stem cell had been identified. We discovered human brown adipocyte
progenitor cells resident in skeletal muscle that under appropriate conditions become fully functional brown
adipocytes, with high levels of UCP1 and a very high metabolic rate. These cells are a unique tool that we
used to develop an assay for identifying compounds with the capacity to recruit new BAT. We recently
converted this assay into high throughput format and employed it to screen 7000+ compounds. We validated
the screening hits, and have selected the most promising of these based on potency, maximal activity, and
the potential to create improved analogs.
In the proposed work, we aim to investigate the Structure Activity Relationship of the most preferred of these
compounds by purchasing and synthesizing a series of novel analogs and evaluating them in vitro. We will
identify those with the highest potential for advancement based on activity and physicochemical and ADME
properties. A lead compound and backup will be selected, and if this work is successful we plan to advance
to PK and in vivo efficacy studies. These will be followed by lead optimization, selection of a development
candidate, and generation of IND-enabling safety data.PROJECT NARRATIVE
Obesity has reached epidemic proportions in the U.S. and globally. While most weight loss agents rely on
suppressing appetite to reduce caloric intake, increasing energy expenditure is another approach to weight
control. Brown adipose tissue (BAT) is a recruitable, thermogenic tissue with the capacity to utilize large
amounts of fat and glucose, and which is present in reduced amounts in obese patients. We discovered a
human BAT progenitor/stem cell and have used this as a tool to discover a small molecule that potently
recruits new BAT cells. Here we propose to generate and test novel analogs of this molecule with improved
activity and physicochemical and ADME properties that would be suitable for a development candidate, with
the aim of increasing brown fat and treating obesity in patients.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- In Vivo Proof of Concept and Target Identification Using Small Molecule Stimulators of Brown Adipogenesis
- Optimization and Pre-Clinical Studies of a Protein Therapeutic for Recruiting Brown Adipocytes
- Establishing In Vivo Proof of Concept of Brown Adipogenesis Using Approved Drugs
- Pre-Clinical Optimization of Human Brown Adipocyte Cell Therapy
- Target Identification of Proteins and Peptides Capable of Recruitment of Brown Ad